Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Pancreatitis and gallbladder disease are recognised class-effect risks associated with GLP-1-based therapies and should be considered even in the absence of specific retatrutide data
Some practitioners do experiment with stretching the time between doses during maintenance
The Bottom Line: Ozempic vs Mounjaro for Weight Loss Here is the clinical bottom line, clearly stated: Ozempic is not licensed for weight loss in the UK Wegovy is the correct licensed weight management product containing semaglutide Mounjaro produces approximately 22.5% average weight loss at maximum dose versus 14.920.7% for Wegovy a meaningful difference for patients seeking maximum results Wegovy has a formal NICE cardiovascular benefit label (April 2026) that Mounjaro does not yet have making it the preferred choice for patients with established CVD Wegovy is cheaper (99.99209.99 vs 139285 at Slinic) important for cost-sensitive patients Wegovy now has a pill option (MHRA June 2026) important for needle-phobic patients Mounjaro is the right choice for patients who want maximum weight loss and can afford it Neither Ozempic off-label nor any unregistered product should be your first choice when licensed alternatives are available from a GPhC-regulated UK pharmacy Side Effects: Ozempic vs Wegovy vs Mounjaro Since Ozempic and Wegovy contain the same drug, their side effect profiles are qualitatively identical the differences are quantitative (higher Wegovy doses produce more side effects than lower Ozempic doses)
The effect of psyllium on fasting blood sugar, HbA1c, HOMA IR, and insulin control: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials
By dividing a weekly dose into two smaller administrations separated by approximately 72 to 84 hours, you reduce the peak concentration after each injection while maintaining a higher trough concentration before the next one
Lifestyle habits
